Posted by Michael Wonder on 23 Nov 2022
Palisade Bio is granted fast track designation from the US FDA for LB1148 for accelerated return of bowel function following GI surgery
22 November 2022 - Palisade Bio today announced that the US FDA has granted fast track designation to LB1148 for the acceleration of time to return of bowel function following surgery.
LB1148, is a broad-spectrum serine protease inhibitor which acts to neutralise digestive enzymes, with the potential to both reduce abdominal adhesions and accelerate the return of bowel function following gastrointestinal surgery.
